Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
about
Emerging drugs for uveitisPro: 'The usefulness of biomarkers in glomerular diseases'. The problem: moving from syndrome to mechanism--individual patient variability in disease presentation, course and response to therapyProtective Effect of Thymoquinone against Cyclophosphamide-Induced Hemorrhagic Cystitis through Inhibiting DNA Damage and Upregulation of Nrf2 ExpressionBiological and immunotoxicity evaluation of antimicrobial peptide-loaded coatings using a layer-by-layer process on titanium.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Is knee osteoarthritis a symmetrical disease? Analysis of a 12 year prospective cohort study.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.Incidence of Cancer in ANCA-Associated Vasculitis: A Meta-Analysis of Observational Studies.Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening.Management of Widespread Skin Thickening in Diffuse Systemic Sclerosis.Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.Evidence-Based Practice Recommendations for Hydration in Children and Adolescents With Cancer Receiving Intravenous Cyclophosphamide.Characteristics and outcome of Goodpasture's disease in children.Adding to complexity: comorbidity in paediatric rheumatic disease.Side-effects of anti-inflammatory therapy in uveitis.State of the art in the treatment of systemic vasculitides.Treatment of granulomatosis with polyangiitis (Wegener's).What investigations are needed to optimally monitor for malignancies in SLE?Pharmacological approaches to CNS vasculitis: where are we at now?Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Cyclophosphamide in dermatology.Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic DiseasesDefining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology.The safety of pharmacological treatment options for lupus nephritis.Cyclophosphamide administration routine in autoimmune rheumatic diseases: a review.Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen.A presentation of cerebritis secondary to granulomatosis with polyangiitis (wegener)Pharmacologic Treatment of Noninfectious Uveitis.Eosinophilic angiitis presenting with a true, fusiform, temporal artery aneurysm.EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.Cuscuta chinensis Ameliorates Immunosuppression and Urotoxic Effect of Cyclophosphamide by Regulating Cytokines - GM-CSF and TNF-Alpha.[Treatment strategies for ANCA-associated vasculitides].Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy.[Urological comorbidities in patients with rheumatoid arthritis : literature review].Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.Decreased prevalence of cancer in patients with multiple sclerosis: A case-control study.[S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].HarnblasenkrebsEffects of the hydroalcoholic extract of Phyllanthus niruri and its isolated compounds on cyclophosphamide-induced hemorrhagic cystitis in mouse
P2860
Q24630848-388DB0BF-56B8-4E68-BF3D-F857E4F6855EQ27015909-D1919CE7-3F99-4F2B-AD08-C7FDC7AD8DC5Q28385767-A9211DEE-97D2-4B8C-8DD0-262E71466CD8Q30397773-DAE6E421-D6AD-4064-9E90-A0EA60944781Q34124711-D4D8BB0A-1D9E-42AC-95A5-54AC16BB75F0Q34392050-3A4BB3CE-7ABD-43D0-9AD8-A29E3103FF04Q34530196-219D30EA-6023-4DFA-AD78-AB5FE16F4D80Q35606909-6AE5582B-8ACE-437E-B81F-2803410FBB3AQ36090959-11683048-2BC7-4D8B-A01C-A98C5C2D0A4CQ36276815-620D1027-109E-4034-B573-7D071A897506Q37003312-D97738CE-EC3B-4187-9EDA-65C78E2F9459Q37100264-17EB99DD-0DBF-4672-8C6F-023BBF35824FQ37550725-302FFDF6-C76A-4D96-AF79-60876E2CCE4EQ38038101-2A98EB1B-6344-49B5-9F94-D4FA0168C7DCQ38048234-9397FD69-6230-48AE-9A6E-DCF2BE297570Q38261127-D0DCEBAD-5328-4561-992D-ED2C5DB95E36Q38263514-650E1115-EB93-4311-8EAF-A12B1AA6234FQ38341601-61787D12-65AD-450D-884A-BC186E83FC0CQ38367994-44DA3CEB-A3F1-4692-AD19-B09EA3103F49Q38630819-5EDB50DD-0F82-43E1-89A4-6892D70B1496Q38641190-651286C6-6E6C-4CBB-A2D8-FE6763340A8CQ38710150-D9B8C43E-77EA-4F31-9F53-DE9315980101Q38711151-BD075606-7525-4C8E-8DB5-D16A29636E9AQ38821066-835FAB27-29E9-4F8F-BED5-507EA8F72750Q38829637-77036382-3EAB-487C-94F1-6645FF770762Q38969688-B80BD3E9-3BCC-4B13-8C3B-9A4FB0F4EA62Q39037182-2BAA24A6-F75F-4AB7-854D-8C3D97C23143Q40002889-64638F04-1474-402F-AC04-FB439FB9F677Q40450258-AD22424B-2A6B-4DAA-95A2-81773F14419DQ40476658-0B0C5C07-EE01-41B6-AD3E-64F9526DCAECQ40684657-7559C312-1EB7-43E3-82B8-04C047595C68Q41031610-FE9D2F15-3A9D-4BC1-B0D2-EBF164BD7833Q41192540-98AECEAC-D05F-4E23-B3DB-F7EA282213DFQ41476938-89AC7628-9671-49B3-B141-3E5573093575Q44306281-4718B863-83C6-42C9-80EF-181C7F44A052Q45031657-185417E5-62CB-4ED4-91F1-48D4DC35DF81Q47094788-520856D9-EC54-407E-BAFA-AEF84BA6137FQ50076914-5D42B16C-24DF-4A51-B945-9F10E2BBF239Q55109644-D9FDDE97-89F7-4C21-8FF7-01B68D44DA37Q58310862-A115B571-BFB3-4C28-AA2A-418A33F50C94
P2860
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Incidence and prevention of bl ...... iseases: a data-driven review.
@ast
Incidence and prevention of bl ...... iseases: a data-driven review.
@en
Incidence and prevention of bl ...... iseases: a data-driven review.
@nl
type
label
Incidence and prevention of bl ...... iseases: a data-driven review.
@ast
Incidence and prevention of bl ...... iseases: a data-driven review.
@en
Incidence and prevention of bl ...... iseases: a data-driven review.
@nl
prefLabel
Incidence and prevention of bl ...... iseases: a data-driven review.
@ast
Incidence and prevention of bl ...... iseases: a data-driven review.
@en
Incidence and prevention of bl ...... iseases: a data-driven review.
@nl
P2860
P356
P1476
Incidence and prevention of bl ...... iseases: a data-driven review.
@en
P2093
Lindsay M Arnold
Peter A Merkel
P2860
P356
10.1002/ART.25061
P577
2010-01-01T00:00:00Z